Canada markets close in 32 minutes
  • S&P/TSX

    19,161.36
    +53.59 (+0.28%)
     
  • S&P 500

    4,124.21
    +61.17 (+1.51%)
     
  • DOW

    34,130.69
    +543.03 (+1.62%)
     
  • CAD/USD

    0.8222
    -0.0022 (-0.27%)
     
  • CRUDE OIL

    63.67
    -2.41 (-3.65%)
     
  • BTC-CAD

    59,278.38
    -7,051.51 (-10.63%)
     
  • CMC Crypto 200

    1,313.92
    -73.98 (-5.33%)
     
  • GOLD FUTURES

    1,826.00
    +3.20 (+0.18%)
     
  • RUSSELL 2000

    2,169.25
    +34.11 (+1.60%)
     
  • 10-Yr Bond

    1.6680
    -0.0270 (-1.59%)
     
  • NASDAQ

    13,149.79
    +118.10 (+0.91%)
     
  • VOLATILITY

    23.09
    -4.50 (-16.31%)
     
  • FTSE

    6,963.33
    -41.30 (-0.59%)
     
  • NIKKEI 225

    27,448.01
    -699.50 (-2.49%)
     
  • CAD/EUR

    0.6802
    -0.0022 (-0.32%)
     

Guardant Health to Report First Quarter Financial Results on May 6, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Source: Guardant Health, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005850/en/

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Courtney Carroll
courtney.carroll@uncappedcommunications.com